Drug delivery and discovery


Efficient delivery of drugs to the site of disease is a crucial parameter in most therapeutic strategies. However, poor solubility and stability of drug compounds or the impenetrable character of biological barriers limits the amounts of drug that accumulates at the desired location in the body. The CBIO group runs a series of projects concerning the development of drug delivery systems capable of transporting therapeutic compounds to improve therapeutic efficacy for range of different diseases. These systems include nanoparticles and micelles comprising lipids or polymers that can encapsulate many classes of drugs, including chemotherapeutics, antibiotics, and immunostimulatory compounds. Other projects are focused on depot formulations for localized and sustained drug activity, and development of new drugs and prodrugs designed to be compatible with the different drug delivery systems. The main focus of the development projects is to improve drug delivery in cancer (see Immunotherapy and cancer vaccines), inflammatory, infectious, and brain diseases, or conditions, where oral drug delivery is paramount. With respect to brain diseases, drug delivery strategies are developed to cross the blood-brain barrier for the treatment of Alzheimer’s disease and brain tumors. Technologies include nano-sized drug carriers and antibody-based therapies. In relation to oral drug delivery, peptide transport across the intestinal epithelium is studied to inform on how large molecules can penetrate this barrier to increase drug delivery and patient compliance (see CitBIO).

Contact

Jonas Rosager Henriksen
Head of Section, Associate Professor
DTU Health Tech
+45 40 58 28 66

Contact

Anders Elias Hansen
Senior Researcher
DTU Health Tech
+45 45 25 81 39

Contact

Kasper Kristensen
Researcher
DTU Health Tech
+45 45 25 81 66

Contact

Gael Clergeaud Veiga
Researcher
DTU Health Tech
+45 45 25 81 35

Contact

Carl Fredrik Melander
Researcher
DTU Health Tech
+45 45 25 81 32